Navigation Links
Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at MarketPublishers.com
Date:10/1/2013

London,UK (PRWEB) October 01, 2013

Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib) and the immunomodulatory drugs such as Revlimid (lenalidomide) and Thalomid (thalidomide) have become the basic treatments for multiple myeloma (MM) leading to the improvement in survival rates. Nevertheless, new treatment options for relapsed/refractory multiple myeloma (RRMM) are required to further improve survival and the quality of life of this group patients, and new drugs, such as Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid), have already started to successfully fulfill this need.

The ever increasing need for innovative therapies for unmet needs/challenging diseases spurs the pace of drug development, either directly or through partnership/in-licensing. Meantime, maturing pipeline, successful launches and new drug approvals sustain the growth trajectory of the biotech companies.

In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
Published: September, 2013
Pages: 44
Price:    US$ 2,500.00
http://marketpublishers.com/report/diagnostics-diseases/cancer/treating-refractory-hematological-malignancies-multiple-myeloma-mm.html

The report offers an insightful overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM). It sheds light on the unmet needs and limitations of the current standard of care for relapsed and refractory MM patients. It describes the competitive scenario and delivers information on the leading biotech companies, covering clinical data of drugs, milestones, and valuation; indicates commercial opportunity in pursuing this therapy area. The research study reviews the early- and late-stage drugs in the clinic, covers key mergers and acquisitions in the area, provides clinical trial details of key drugs in pipeline, and offers an au-close look at the future of the drugs in the late-stage pipeline.

Report Scope:

  •     Comprehensive disease profile, review of unmet needs and description of the current standard of care.
  •     Extensive overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM).
  •     Data on the drugs in the pipeline: NDMM & RRMM – mechanism of action (MoA) and clinical stage of development.
  •     Clinical trial details of key drugs in pipeline.
  •     Discussion of the important issues related to the therapeutic area.
  •     Information on M&A and licensing deals that have taken place over the past five years.
  •     Evaluation of in-licensing and/or M&A opportunities.
  •     Insights into the competitive environment and detailed company profiles.
  •     Future outlook.

More new research reports by the publisher can be found at MP Advisors page.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11183653.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... New Jersey (PRWEB) , ... March 23, 2017 ... ... developer of herbal-based and non-steroidal skincare products, was awarded as winners of American ... innovation products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... 23, 2017 , ... The Boulevard is honored to host Shriners and Masons ... be located in the Main West Entrance of The Boulevard (in front of JCPenney). ... is necessary and each child with a parent or guardian will be photographed for ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... has selected HealthiPASS, an innovative patient - centric payment system, to expand its ... massive improvements in the patient financial experience. , “At Ogden Clinic, we ...
(Date:3/23/2017)... ... March 23, 2017 , ... “More Corruption”: a simple and strong explanation of the God’s ... the rulers of Heaven was asked by God to write a book about Him. , ... just because I kept my commitment to the Lord God. They have not walked in ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 NeuroVive Pharmaceutical ... today announced that the English version of the Annual report ... www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical AB is a ... discovery and development of medicines that preserve mitochondrial integrity and ...
(Date:3/22/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Respiratory care ... 10.9% over the next decade to reach approximately $38.27 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... Under the impetus of the fast-growing ... increased year by year at the CAGR of ... market size will maintain the growth rate of ... billion in 2021, thanks to severe aging, the ... agents and supporting policies. At present, Chinese ...
Breaking Medicine Technology: